|Ms. Heather Bresch||CEO & Exec. Director||4.23M||N/A||1969|
|Mr. Rajiv Malik||Pres & Exec. Director||3.51M||N/A||1961|
|Mr. Kenneth S. Parks||Chief Financial Officer||1.91M||N/A||1963|
|Mr. Anthony Mauro||Chief Commercial Officer||1.95M||84.15k||1973|
|Mr. Daniel M. Gallagher Jr.||Advisor||2.08M||N/A||1973|
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Mylan N.V.’s ISS governance QualityScore as of 29 July 2019 is 7. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 7; Compensation: 8.